Goldline Pharmaceutical IPO Day 2 Subscription Status At 37.70x So Far
By HDFC SKY | Published at: May 13, 2026 12:48 PM IST
Goldline Pharmaceutical IPO subscribed 37.70 times on Day 2, led by strong retail and NII demand as of May 13, 2026.
Mumbai, May 13: Goldline Pharmaceutical IPO was subscribed 37.70 times as of 10:59 AM on Day 2 of bidding on May 13, 2026, according to exchange data.
The SME IPO, valued at nearly ₹11.61 crore, opened for subscription on May 12, 2026, and will close on May 14, 2026. The public issue is priced in the range of ₹41 to ₹43 per share and is proposed to list on the BSE SME platform.
The issue received strong traction from retail investors and non-institutional investors during the second day of bidding, while the qualified institutional buyer segment saw relatively moderate participation.
Goldline Pharmaceutical IPO Day 2 Subscription Status
Goldline Pharmaceutical IPO was subscribed 37.70 times overall as of 10:59 AM on May 13, 2026.
| Category | Subscription (x) | Shares Offered | Shares Bid For |
| QIB (Ex Anchor) | 1.31 | 5,40,000 | 7,05,000 |
| NII | 45.50 | 3,90,000 | 1,77,45,000 |
| Retail Individual Investors | 56.15 | 9,00,000 | 5,05,32,000 |
| Total | 37.70 | 18,30,000 | 6,89,82,000 |
Category-wise Goldline Pharmaceutical IPO Subscription Status
| Investor Category | Subscription (x) |
| Retail Individual Investors | 56.15 |
| NII | 45.50 |
| bNII (> ₹10 lakh) | 44.17 |
| sNII (< ₹10 lakh) | 48.09 |
| QIB (Ex Anchor) | 1.31 |
| Anchor Investors | 1.00 |
| Market Maker | 1.00 |
Goldline Pharmaceutical Day-wise Subscription Summary
| Date | QIB (Ex Anchor) | NII | Retail Investors | Total Subscription |
| May 12, 2026 (Day 1) | 1.31x | 24.46x | 34.07x | 22.35x |
| May 13, 2026 (Day 2) | 1.31x | 45.50x | 56.15x | 37.70x |
Retail participation strengthened further on the second day of the issue, while the NII segment also recorded a sharp rise in bids compared with the opening day.
Goldline Pharmaceutical IPO Timeline
| Event | Date |
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Initiation of Refunds | May 18, 2026 |
| Credit of Shares | May 18, 2026 |
| Listing Date | May 19, 2026 |
Brief Overview Of The IPO
Goldline Pharmaceutical IPO is a book-built SME issue comprising a fresh issue of 25.62 lakh equity shares. The total issue size aggregates to nearly ₹11.61 crore at the upper end of the price band.
The IPO is priced at ₹41 to ₹43 per share, with a face value of ₹10 each. The minimum lot size for retail investors is 3,000 shares, while the minimum investment amount stands at ₹2.58 lakh for two lots at the upper price band.
The company proposes to list on BSE SME. Bigshare Services Pvt. Ltd. is the registrar to the issue, while Cumulative Capital Pvt. Ltd. is the book-running lead manager.
Goldline Pharmaceuticals is engaged in the marketing of pharmaceutical products under the ‘Goldline’ brand. Its portfolio spans multiple therapeutic categories including orthopaedics, ENT, gastroenterology, neurology, urology, cardiology and paediatrics.
Source;
- https://www.bseindia.com/markets/publicissues/displayipo?id=4573&type=IPO&idtype=1&status=L&IPONo=7716&startdt=12%2F05%2F2026
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
